1 Introduction
==============

Drug repurposing (DR) is a strategy to identify novel therapeutic purposes for existing drugs with a goal to expand the scope of the original medical indication of known drugs ([@btaa437-B29]). This task is of great pharmaceutical significance as the *de novo* drug discovery is known to be costly and lengthy. The total cost of developing a drug ranges from \$2 billion to \$3 billion and it takes at least 13--15 years to bring a single drug to market ([@btaa437-B60]). By contrast, DR offers a fast and cost-effective means for drug candidate discovery. For example, the repurposed drug candidate has proven to be sufficiently safe through preclinical assessments, thus resulting in a shortened period of clinical evaluation.

Recently, large-scale databases such as protein--protein interaction (PPI) networks, drug--target interactions and drug--disease associations are rapidly growing and increasingly accessible. The wealth of drug-related data presents great opportunities to generate novel insights surrounding drug mechanisms and develop *in silico* DR methods to accelerate drug discovery. However, *in silico* DR is challenging due to the molecular heterogeneity of disease and diverse drug--disease associations. For example, the complexity of molecular target interactions such as PPI remains to be elucidated. Without knowledge from a broader network of the molecular determinants of disease and drug targets, we are unable to develop efficacious drug treatment for complex diseases ([@btaa437-B18]). Therefore, DR requires deep exploration of a multimodal biological network including drug--disease, drug/disease--protein and protein--protein associations in an integrative context.

Among various biomedical interactions, the importance of the complex PPI network is broadly recognized in biological systems and the development of disease states ([@btaa437-B48]). In other words, PPIs are at the center of almost every cellular process from cell motility to DNA replication. Thus understanding PPI mechanism could greatly help elucidate the function of a known or novel protein and its role in a known biological pathway, which can be a key factor for justifying DR. Existing approaches using PPIs are often focused on using predefined descriptors to represent protein information such as the overlap of PPI closeness. However, they cannot fully explore the potential information within PPI in an integrative context, which requires modeling interdomain information fusion to characterize drug's pharmacological action and guide a roadmap for DR assessment.

Previous studies in DR were primarily focused on drug and disease activities to uncover statistical associations between them ([@btaa437-B9]; [@btaa437-B46]; [@btaa437-B58]). These analyses worked on a single data modality such as gene expression or drug--target interactions, only capturing partial information of the heterogeneous network. In addition, these methods cannot consider the important topological information among different biological networks. To address this limitation, there has been a growing number of efforts to incorporate various data sources for boosting the accuracy of drug repositioning ([@btaa437-B17]; [@btaa437-B19]; [@btaa437-B28]; [@btaa437-B35]; [@btaa437-B39]; [@btaa437-B62]; [@btaa437-B64]). These approaches integrate multiple information sources such as chemical fingerprint, interaction network closeness of drug targets and correlation between drug side effects. However, these approaches with engineering-based features were unable to capture graph-structured information such as chemical molecules of drugs and PPI network knowledge. Therefore, graph-based model architectures become highly desired for incorporating multiscale, graph-based knowledge and improving the model performance in DR.

Graph convolutional networks (GCNs) ([@btaa437-B26]) extend deep-learning approaches specifically designed for processing graph-based data in various graph-related tasks. In principle, GCNs perform a convolution by aggregating the neighbor nodes' information to learn node representations in the entire graph. GCN has unique advances in its automation on feature extraction from raw graph-structured inputs. Recently, a handful of GCN-based methods in drug--drug and drug--target interaction predictions have proved the usefulness of GCN-based models for drug information extraction ([@btaa437-B11]; [@btaa437-B15]; [@btaa437-B36]; [@btaa437-B67]). However, exploring GCN-based networks for deep understanding multiscale biological characteristics of drug data remains to be fully elucidated. Specifically, a notable limitation for conventional GCN-based methods is that same node attributes should always be assumed. Thus, these approaches view the multirelational networks as a global graph, completely ignoring distinct node features from different domains. For example, node features in drug and protein domains actually follow separate statistical distributions. But conventional GCNs can only leverage neighboring nodes in a single graph thus are quite difficult to measure correlation between the two separate domains.

To address all challenges above, we propose a bipartite graph convolution network approach, termed BiFusion, for *in silico* DR. The key motivation is to model interactions between diverse biological domains through bipartite graphs. Unlike previous GCN-based methods, our model enables interdomain information fusion with a bipartite graph convolution operation. To allow information fusion, our model learns to represent different features from heterogeneous nodes into a unified embedding space, where protein nodes serve as a bridge for message passing within complex biological networks. This design differs from conventional GCN that is limited on node representation in a single graph. Overall, our major contributions can be summarized as follows: (i) To the best of our knowledge, this article proposed the first bipartite GCN-based approach for *in silico* DR, assembling interactions across protein, drug and disease domains from large-scale databases. (ii) We proposed a novel end-to-end graph learning framework that can effectively integrate multirelational interaction data for DR, yielding improved performance than baseline methods. (iii) Our analysis provided insights into better extracting and fusing information from the PPI network for DR.

2 Related works
===============

We briefly review computational approaches for DR and related researches on GCNs.

2.1 *In silico* DR
------------------

Numerous studies have used single data source to identify drug indications. Different information modalities include structural features of compounds (or proteins) ([@btaa437-B9]), genetic activities ([@btaa437-B46]) and phenotypic profiles such as side effects of drugs ([@btaa437-B58]). However, these methods failed to offer an unbiased perspective for predicting drug--disease associations due to the potential noise in the single information source. In addition, these methods cannot model important topological information among different biological networks. In response, current methods can be categorized into similarity-based and network-based approaches.

Most of similarity-based approaches are integrative methods using the heterogeneous information ([@btaa437-B17]; [@btaa437-B28]; [@btaa437-B39]; [@btaa437-B64]). They rely on the assumption that similar drugs are indicated for similar diseases. These methods utilize shared characteristics between drugs such as drug--targets, chemical structures and adverse effects, and then constructed similarity features to build computational models. For example, PREDICT ([@btaa437-B17]) is a similarity-based framework integrating drug--drug similarity (based on drug--protein interactions, sequence and gene-ontology) and disease--disease similarity (disease--phenotype and human phenotype ontology), authors used them as key features applying logistic regression to predict similar drugs for similar diseases.

Network-based approaches ([@btaa437-B6], [@btaa437-B7]; [@btaa437-B19]; [@btaa437-B35]; [@btaa437-B62]) model graph-structured information among different biological networks to boost the performance for DR. Typically, in these models, the nodes in the networks represent either drug, disease or gene products and edges denote the interactions or relationships among them. For example [@btaa437-B6] identified hundreds of new drug--disease associations by quantifying the network proximity of disease genes and drug targets in the human protein--protein interactome. The deepDR ([@btaa437-B62]) learnt high-level features of drugs from the heterogeneous networks by a multimodal deep autoencoder and applied a variational autoencoder to infer candidates for approved drugs. However, deepDR considered information sources in the drug domain only without interactions in the disease domain.

Bipartite graph comprises a set of nodes decomposed into two disjoint sets ([@btaa437-B42]; [@btaa437-B61]), which is a natural representation for modeling complex items of biological systems and their interactions. Extensive studies have revealed the feasibility of bipartite graphs and their impact in the field of network biology ([@btaa437-B42]). For example [@btaa437-B61] built a bipartite graph to analyze relationships between drug targets and disease--gene products. [@btaa437-B27] performed a bipartite graph approach to analyze the relationships between human genetic diseases. In the field of DR, [@btaa437-B28] developed a bipartite drug--target network method using drug pair similarity integrated drug chemical structure similarity, common drug targets and their interactions. [@btaa437-B66] also constructed a bipartite graph model with known relationships between drugs and their target proteins. However, most of these methods heavily relied on predefined drug similarity features and ignored the important information sources in the disease domain. Although they utilized the PPI information, the relationships between drug targets and disease--gene products in the context of biological interaction network have not been investigated.

2.2 Graph convolutional networks
--------------------------------

GCN ([@btaa437-B26]) has opened a new paradigm for graph learning and achieved leading performance in machine-learning tasks. The major motivation of GCN roots in generalizing convolutional neural network (CNN) in the graph domain. Increasing amount of graph-structured data necessitate the use of GCN-based models for addressing with complex relationships and interdependencies of objects in non-Euclidean spaces. Traditional CNN models are no longer applicable on these tasks because structural information are not considered or sufficiently used in feature extraction in graphs. In addition, traditional graph-based approaches are inflexible at scale as they often rely on hand-engineered features including summary graph statistics and kernel functions. By contrast, GCN-based models are designed to capture the dependence of graphs via a recursive neighborhood aggregation scheme, where each node aggregates feature vectors of its neighbors to update its new node features. Thus, GCNs demonstrate their superiority for graph-related tasks given their ability to naturally integrate the feature attributes of graph-structured data and learn intrinsic features from raw graph-structured inputs.

GCN extends the idea of the graph neural network (GNN) ([@btaa437-B47]). Specifically, a graph $\mathcal{G} \in \mathbb{G}$ can be denoted by $\mathcal{G}(\mathcal{V},\mathcal{E})$ consisting of a vertex set $\mathcal{V} = \left\{ v_{i} \right\}_{i = 1}^{N_{\mathcal{V}}}$ and edge set $\mathcal{E} = \left\{ e_{j} \right\}_{j = 1}^{N_{\mathcal{E}}},\,{\overset{\rightarrow}{h}}_{v_{i}} \in \mathbb{R}^{N}$ is the node feature of vertex *v~i~*. A general GNN layer can be defined as follows: $$g_{\mathcal{E}}\left( v_{i} \right) = \rho\left( {\overset{\rightarrow}{h}}_{v_{i}},\text{agg}\left( \left\{ W_{v_{i},v_{j}}{\overset{\rightarrow}{h}}_{v_{j}} \middle| v_{j} \in \mathcal{N}_{v_{i}}^{\mathcal{E}} \right\} \right) \right),$$where $W \in \mathbb{R}^{M \times N}$ is a learnable matrix transforming *N*-dimensional features to *M*-dimensional features, the $\text{agg}$ is a permutation-invariant aggregation operation such like element-wise mean-pooling and the *ρ* operator can be a nonlinear activation function such as ReLU. $\mathcal{N}_{v_{i}}^{\mathcal{E}}$ is the neighborhood of the node *v~i~* connected by $\mathcal{E}$ in $\mathcal{G}$. In GCN, these two operators are integrated as follows: $$g_{\mathcal{E}}\left( v_{i} \right) = \text{ReLU}\left( W \cdot \text{Mean}\left( \left\{ h_{v_{j}} \middle| v_{j} \in \mathcal{N}_{v_{i}}^{\mathcal{E}} \cup \left\{ v_{i} \right\} \right\} \right) \right).$$

Following on this work, there is increasing interest in extending and improving GCN with more powerful aggregation function such as GraphSAGE ([@btaa437-B20]) and Graph Attention Network (GAT) ([@btaa437-B54]). GAT uses an attention mechanism on the node features to construct the weighting kernel as $W_{v_{i},v_{j}} = \alpha_{v_{i},v_{j}}W$. The attention mechanism is a single-layer feedforward neural network, parametrized by a weight vector $\overset{\rightarrow}{a} \in \mathbb{R}^{2M}$ and applying the LeakyReLU nonlinearity. The weighting coefficients computed by the attention mechanism can be expressed as: $$\alpha_{v_{i},v_{j}} = \frac{\,\text{exp}\,\left( {\rho\left( {{\overset{\rightarrow}{a}}^{T}\left\lbrack W{\overset{\rightarrow}{h}}_{v_{i}} \middle| \middle| W{\overset{\rightarrow}{h}}_{v_{j}} \right\rbrack} \right)} \right)}{\sum\limits_{v_{k} \in \mathcal{N}_{v_{i}}^{\mathcal{E}}}{\,\text{exp}\,}\left( {\rho\left( {{\overset{\rightarrow}{a}}^{T}\left\lbrack W{\overset{\rightarrow}{h}}_{v_{i}} \middle| \middle| W{\overset{\rightarrow}{h}}_{v_{k}} \right\rbrack} \right)} \right)}$$where *T* represents transposition and $||$ is the concatenation operation.

Despite advances of GCNs, applying them to bipartite graphs in biomedical domains was seldom explored. The main technical challenge is that node features in different domains of bipartite graphs present quite distinct characteristics. Therefore, it is insufficient to simply apply conventional GCNs to model the connections between multiple domains. To build and explore such connection, we identified that recent studies ([@btaa437-B22]; [@btaa437-B40]) have shown the effectiveness of bipartite GNNs on modeling interconnected graphs.

Conceptually, our research draws inspiration from recent progress of applying GCNs in biomedicine. For example [@btaa437-B67] achieved state-of-the-art results in predicting polypharmacy side effects using GCN. [@btaa437-B12] showed the effectiveness of GCN in the task of protein interface prediction. [@btaa437-B23] proposed a graph convolution framework to learn molecular representations for data-driven tasks considering both node and edge features.

3 Datasets
==========

We formulated the problem of DR as a drug--disease link prediction task using multimodal interaction data. We constructed a multirelational graph network using multiple biomedical datasets that allow systematic evaluations for DR. Specifically, drug--disease interaction networks contain drugs therapeutic indications. Drug--protein/ disease--protein networks describe the proteins targeted by drugs/diseases. Finally, protein--protein networks contain interaction relationships between proteins. Below we describe details of the datasets to construct the graph network in our study ([Fig. 1](#btaa437-F1){ref-type="fig"}).

![Overview of our heterogeneous information network. The multirelational network has 592 disease, 1012 drug and 13 460 protein nodes connected by 3204 drug--disease, 7713 drug--protein, 104 716 disease--protein and 141 296 protein--protein edges](btaa437f1){#btaa437-F1}

3.1 Drug--disease associations
------------------------------

For this study, we collected 3204 known therapeutic indications of drugs from repoDB database ([@btaa437-B4]), in which 6677 approved indications were drawn from DrugCentral ([@btaa437-B52]). Only FDA-approved small-molecule drugs were considered and generic name of each drug were standardized by Medical Subject Headings (MeSH) ([@btaa437-B31]) and Unified Medical Language System vocabularies ([@btaa437-B1]). We also mapped drugs to PubChem ([@btaa437-B24]) with compound ID to get their chemical structure information represented by simplified molecular-input line-entry system (SMILES) string ([@btaa437-B57]). Most of drugs (75%) treat less than 3 indicated diseases; only 4% of drugs treat more than 10 diseases. 70% of the diseases have less than 5 drugs; 16% of the diseases have 5--10 drugs; 14% of diseases have more than 10 drugs.

3.2 Drug--protein and disease--protein associations
---------------------------------------------------

Drug targets were obtained from the DGIdb ([@btaa437-B8]) database which consolidates drug gene interactions and potentially druggable genes into a single resource from papers, databases and web resources. DGIdb normalized content from 30 disparate sources using a combination of expert curation and text mining, resulting in 29 783 drug gene interactions which cover 41 100 genes and 9495 drugs. We pulled target protein-coding genes of a given drug from DGIdb, then mapped genes to proteins with gene names. Our drug--protein interaction network covers 7713 drug--protein interactions between 1012 drugs and 1681 proteins.

Disease--protein associations were extracted from DisGeNET ([@btaa437-B44]), one of the largest available collections of genes and variants involved in human diseases. DisGeNET integrates data from expert curated databases with information gathered through text mining the scientific literature, including various resources such as the comparative toxicogenomics database (CTD) ([@btaa437-B10]) and online mendelian inheritance in man (OMIM) ([@btaa437-B21]). We pulled protein-coding genes of a given disease and then map them to corresponding products. Our curated disease--protein interaction network covers 104 716 disease--protein associations between 592 diseases and 9941 proteins.

3.3 Protein--protein interactions
---------------------------------

We used the human PPIs compiled by [@btaa437-B37] which is an unweighted and undirected network with 13 460 proteins and 141 296 physical interactions. The network contains physical interactions with experimental support, such as regulatory interactions, metabolic enzyme-coupled interactions and signaling interactions. The PPI network is approximately scale-free and shows other typical characteristics as observed previously in many other biological networks, such as high clustering and short pathlengths.

The final multirelational network after linking entity vocabularies across different modalities and databases has 592 disease, 1012 drug and 13 460 protein nodes connected by 3204 drug--disease, 7713 drug--protein, 104 716 disease--protein and 141 296 protein--protein edges.

4 Materials and methods
=======================

4.1 Interdomain message passing through bipartite graph convolution
-------------------------------------------------------------------

A bipartite graph $\mathcal{BG}(\mathcal{U},\mathcal{V},\mathcal{E})$ is a graph $\mathcal{G}(\mathcal{U} \cup \mathcal{V},\mathcal{E})$ where $\mathcal{U}$ and $\mathcal{V}$ denote two sets of the two domains of vertices (nodes). *u~i~* and *v~j~* denote the *i*th and *j*th node in $\mathcal{U}$ and $\mathcal{V}$, respectively, where $i = 1,2,\ldots,M$ and $j = 1,2,\ldots,N$. All edges of a bipartite graph are strictly between $\mathcal{U}$ and $\mathcal{V}$ (i.e. $\mathcal{E} = \left\{ (u,v) \middle| u \in \mathcal{U}),v \in \mathcal{V} \right\}$), $e_{ij}$ denotes the edge between *u~i~* and *v~j~*. The features of two sets of nodes can be denoted by *X~u~* and *X~v~* where $X_{u} \in \mathbb{R}^{M \times P}$ is a feature matrix with ${\overset{\rightarrow}{x}}_{u_{i}} \in \mathbb{R}^{P}$ representing the feature vector of node *u~i~*, and $X_{v} \in \mathbb{R}^{N \times Q}$ is defined similarly.

Bipartite graph convolution only performs message passing and node feature aggregation through interdomain edges as the intradomain edges are absent in bipartite graphs. For the message passing $\text{MP}_{v\rightarrow u}$ from domain $\mathcal{V}$ to $\mathcal{U}$, we define a general bipartite graph convolution (bg) as: $$\text{bg}_{\mathcal{E}}\left( u_{i} \right) = \rho\left( {\text{agg}\left( \left\{ W_{u_{i},v_{j}}{\overset{\rightarrow}{x}}_{v_{j}} \middle| v_{j} \in \mathcal{N}_{u_{i}}^{\mathcal{E}}) \right\} \right)} \right),$$where $\mathcal{N}_{u_{i}}^{\mathcal{E}}$ is the neighborhood of the node *u~i~* connected by $ɛ$ in $\mathcal{BG}(\mathcal{U},\mathcal{V},\mathcal{E})$ (i.e. $\mathcal{N}_{u_{i}}^{\mathcal{E}} \subset \mathcal{V}$). Note that any unipartite graph convolution defined on $\mathcal{G}(\mathcal{V},\mathcal{E})$ can be formulated as a bipartite graph convolution defined on $\mathcal{BG}(\mathcal{V},\mathcal{V},\mathcal{E})$.

Our bipartite graph convolution layers uses GAT as the backbone, termed as bipartite graph attention convolution layer (bga). As the attention mechanism considers features of two sets of nodes, we specifically define a learnable matrix $W^{u} \in \mathbb{R}^{P \times S}$ (resp. $W^{v} \in \mathbb{R}^{Q \times S}$) for *X~u~* (resp. *X~v~*). The bga can be formulated as: $$\text{bga}_{\mathcal{E}}\left( u_{i} \right) = \text{ReLU}\left( {\sum\limits_{v_{j} \in \mathcal{N}_{u_{i}}^{\mathcal{E}}}\alpha_{u_{i},v_{j}}W^{v}{\overset{\rightarrow}{x}}_{v_{j}}} \right)$$where the weighting coefficients can be expressed as: $$\alpha_{u_{i},v_{j}} = \frac{\,\text{exp}\,\left( {\rho\left( {{\overset{\rightarrow}{a}}^{T}\left\lbrack W^{u}{\overset{\rightarrow}{x}}_{u_{i}} \middle| \middle| W^{v}{\overset{\rightarrow}{x}}_{v_{j}} \right\rbrack} \right)} \right)}{\sum\limits_{v_{k} \in \mathcal{N}_{u_{i}}^{\mathcal{E}}}{\,\text{exp}\,}\left( {\rho\left( {{\overset{\rightarrow}{a}}^{T}\left\lbrack W^{u}{\overset{\rightarrow}{x}}_{u_{i}} \middle| \middle| W^{v}{\overset{\rightarrow}{x}}_{v_{k}} \right\rbrack} \right)} \right)}$$

4.2 Model framework
-------------------

We cast drug discovery task as a link prediction problem by fusing information from a heterogeneous network incorporating drug, disease and protein relationships. More specifically, we show that the heterogeneous network can be represented by an undirected graph $\mathcal{G}(\mathcal{V},\mathcal{E})$ with three sets of nodes: drugs ($\mathcal{V}^{D}$), diseases ($\mathcal{V}^{S}$) and proteins ($\mathcal{V}^{P}$). The initial features of these three sets of nodes are $X_{\mathcal{V}^{D}},\, X_{\mathcal{V}^{S}}$ and $X_{\mathcal{V}^{P}}$, respectively. $\mathcal{E}$ consists of three interdomain edges including drug--disease associations ($\mathcal{E}^{\text{DS}}$), drug--protein target relationship ($\mathcal{E}^{\text{DP}}$) and disease--protein target relationship ($\mathcal{E}^{\text{SP}}$), and one intradomain edges of PPI network ($\mathcal{E}^{\text{PP}}$).

Our model operates directly on the graph $\mathcal{G}(\mathcal{V},\mathcal{E})$ with encoder--decoder architecture ([Fig. 2A](#btaa437-F2){ref-type="fig"}). The encoder is a bipartite GCN learning the embedding representations for all graph nodes. It fuses heterogeneous information through message passing across drug, disease and protein nodes. The decoder is a multilayer perceptron neural network decoder using drug and disease node embeddings to reconstruct drug--disease association matrix.

![Overview of BiFusion model architecture. (**A**) The pipeline of BiFusion contains a bipartite GCN encoder and a MLP decoder. The encoder takes similarity features of drug and disease nodes as inputs, and generates drug--disease pair embeddings by fusing heterogeneous information through message passing across drug, disease and protein nodes. Each BiFusion layer consists of three computing steps shown in the following subfigures. BiFusion decoder takes pair embeddings to produce prediction score and reconstruct drug--disease association matrix. (**B**) The first step in BiFusion layer: a single bipartite graph attention convolution layer is applied to project information from drug and disease domains to protein domain. (**C**) The second step in BiFusion layer: a single layer graph attention convolution layer is applied within PPI network. (**D**) The third step in BiFusion layer: another bipartite graph attention convolution layer is used to update drug and disease features based on learnt protein node embeddings](btaa437f2){#btaa437-F2}

4.3 Node feature representation
-------------------------------

We applied zero-initialization for all protein nodes and defined similarity measures for initializing features for drug and disease nodes.

-   **Chemical-based drug similarity measure**: Canonical SMILES of the drug molecules were used from PubChem. The similarity score between two drugs is computed based on their fingerprints according to the two-dimensional Tanimoto score ([@btaa437-B51]).

-   **Graph-based disease similarity measure**: We used MeSH term ([@btaa437-B31]) as disease descriptor for constructing similarity measures. Given that the structure of MeSH is a directed acyclic graph which enables the comparison of semantic similarity in the graph, we applied the graph-based method proposed by [@btaa437-B55] to measure similarity between disease MeSH terms.

4.4 Bipartite graph convolutional encoder
-----------------------------------------

Each layer of our bipartite graph convolutional encoder consists of three computing steps. First, we applied a single bipartite graph attention convolution layer to pass the message of drugs and diseases to target proteins simultaneously. Conceptually, we can view this step as projecting information from macro level (e.g. information in drugs and disease domains) to micro level (e.g. protein space). This message passing step is formulated as follows: $$\left\{ \begin{array}{l}
{\text{MP}_{\mathcal{V}^{D}\rightarrow\mathcal{V}^{P}}^{(k)}:h_{v_{i}^{p}}^{{(k)}_{1}} = \text{bga}_{\mathcal{E}^{\text{DP}}}\left( v_{i}^{p} \right)} \\
{\text{MP}_{\mathcal{V}^{S}\rightarrow\mathcal{V}^{P}}^{(k)}:h_{v_{i}^{p}}^{{(k)}_{2}} = \text{bga}_{\mathcal{E}^{\text{SP}}}\left( v_{i}^{p} \right)} \\
\end{array} \right.$$where *k* indicates the layer index and $h_{v_{i}^{p}}^{(k)}$ are hidden embeddings of nodes $v_{i}^{p}$ (when *k *=* *0, $h_{v_{i}^{p}}^{(0)} = x_{v_{i}^{p}}$). We concatenated the results of two message passing processes into a unified embedding representation. Therefore, the updated embeddings of protein nodes can be written as: $$\left. H_{\mathcal{V}^{P}}^{(k)} = H_{\mathcal{V}^{P}}^{{(k)}_{1}} \middle| \middle| H_{\mathcal{V}^{P}}^{{(k)}_{2}} \right.$$

In the second step, to enhance domain fusion and model the relationships between drug targets and disease--gene products, we applied a single layer GAT within our PPI network. The intuition behind this step is that GAT can enable feature smoothing between protein neighborhood nodes, and a drug is more likely to treat a disease if they are nearby in protein space. This layer performs intradomain message passing that allows information fusion in protein space and depict complex interactions between drugs and diseases. Therefore, protein nodes serve as a bridge of message passing within our multirelational graph. In each layer, GAT propagates node hidden embeddings across edges of PPI network, which is defined as: $$\text{MP}_{\mathcal{V}^{P}\rightarrow\mathcal{V}^{P}}^{(k)}:h_{v_{i}^{p}}^{(k)} = \text{bga}_{\mathcal{E}^{\text{PP}}}\left( v_{i}^{p} \right)$$

Finally, we utilized the nonlinear graph information captured by protein nodes to update hidden embeddings of drug and disease nodes. In particular, we applied another bipartite graph attention convolution layer to project protein embeddings back to drug and disease domains. Therefore, the third step can be viewed as an integrative graph method to learn drug and disease representations through closeness in PPI network. For those drugs and diseases that share target proteins, this step will help to further make their features similar. The updated feature representations of drug and disease nodes can be written as: $$\left\{ \begin{array}{l}
{\text{MP}_{\mathcal{V}^{P}\rightarrow\mathcal{V}^{D}}^{(k)}:h_{v_{i}^{d}}^{(k)} = \text{bga}_{\mathcal{E}^{\text{DP}}}\left( v_{i}^{d} \right)} \\
{\text{MP}_{\mathcal{V}^{P}\rightarrow\mathcal{V}^{S}}^{(k)}:h_{v_{i}^{s}}^{(k)} = \text{bga}_{\mathcal{E}^{\text{SP}}}\left( v_{i}^{s} \right)} \\
\end{array} \right.$$

We summarize our bipartite graph convolutional encoder in [Figure 2B--D](#btaa437-F2){ref-type="fig"}.

4.5 Multilayer perceptron neural network decoder
------------------------------------------------

Our network decoder applies a multilayer perceptron to reconstruct links in the drug--disease interaction graph. In particular, using embeddings of drug node $h_{v_{i}^{d}}$ and disease node $h_{v_{j}^{s}}$ returned by the encoder, we concatenated two embeddings to represent the drug--disease pair and then fed into the decoder. In particular, decoder scores a drug--disease pair $\left( {v_{i}^{d},v_{j}^{s}} \right)$ through a three-layer $\text{MLP}$ neural network representing how likely it is that the drug can be indicated for the disease: $$\text{MLP}\left( {v_{i}^{d},v_{j}^{s}} \right) = \text{MLP}\left( h_{v_{i}^{d}} \middle| \middle| h_{v_{j}^{s}} \right)$$

Then we applied a sigmoid function *σ* to compute probability of edge $\left( {v_{i},v_{j}} \right)$ : $$p^{ij} = \sigma\left( {\text{MLP}\left( {v_{i}^{d},v_{j}^{s}} \right)} \right)$$

4.6 Model training
------------------

During model training, we optimized model parameters using the cross-entropy loss in an end-to-end fashion. Followed previous studies ([@btaa437-B38]), we trained the model through negative sampling. Specifically, for each positive drug--disease edge $\left( {v_{i},v_{j}} \right)$, we sampled a random edge $\left( {v_{i},v_{k}} \right)$ as a negative example. This is achieved by replacing a drug or disease node *v~j~* with node $v_{k}$ that is selected randomly according to a sampling distribution $P_{s}$ ([@btaa437-B38]). We calculated the final loss function by considering all edges. To optimize the model, we used the Adam optimizer ([@btaa437-B25]) and initialized weights as described in [@btaa437-B16]. To generalize well to unobserved data, we trained the model in a denoising setup by randomly dropping out all outgoing messages of a particular node with a fixed probability. In particular, during the message passing process in encoder, individual outgoing messages across multirelational edges are dropped out independently, making embeddings more robust against the presence or absence of single edges. We also apply regular dropout ([@btaa437-B50]) to the hidden layer units in MLP decoder.

5 Experiments
=============

5.1 Evaluation metrics
----------------------

We conduct 10-fold cross validation to evaluate the model performance. All known drug--disease associations are randomly divided into 10 subsets with equal size. A matching number of unknown pairs were selected as negative samples in training and testing sets through negative sampling strategy. In each cross-validation trial, one subset is taken in turn as the test set, whereas the remaining subsets constitute the training set. We selected model hyperparameters by performing cross validation on the training set. We measure the prediction performance using three criteria: area under the receiver-operating characteristic (AUROC), area under the precision--recall curve (AUPRC) and overall accuracy, which are widely used for drug indication prediction tasks. As the prediction performance can vary considerably across diseases and drugs, we further report the disease/drug-centric accuracy, which is the average of balanced accuracy of all drug--disease pair subsets clustered by disease/drug nodes. To reduce the data bias, we performed 100 independent cross-validation runs and reported the full distribution of average testing performance of all evaluation metrics. In addition, during each random run, a different sampled negative set and partition of the dataset were used. To prevent information leakage in the evaluation, we ensure that only drugs and diseases seen in the training set were used to construct similarity features.

5.2 Method comparison
---------------------

We compare the performance of our model against the several competing approaches. Specifically, BiFusion uses a two-layer architecture with 256 and 128 hidden units in each layer, and a dropout rate of 0.1 in all experiments.

-   **GCN** ([@btaa437-B67]) includes encoder and decoder modules. The encoder is a conventional GCN operating on our multimodal graph of protein--protein, drug--protein and disease--protein interactions. The decoder is a tensor factorization model using node embeddings to model drug--disease associations.

-   **DeepWalk** ([@btaa437-B43]) learns latent node representations of our heterogeneous information network based on local information obtained from truncated random walks. Drug--disease pairs are represented by concatenating latent drug and disease node representations. We used pair representations as inputs to train a logistic regression classifier.

-   **Collective variational autoencoder (cVAE)** ([@btaa437-B5]; [@btaa437-B62]) simultaneously recovers drug--disease association matrix and side information using a variational autoencoder. Specifically, drug--disease association matrix and drug--drug similarity matrix are encoded and decoded collectively through the same inference network and generation network.

-   **Sparse linear methods with side information (SSLIM)** ([@btaa437-B41]) learns a sparse coefficient matrix to do top-N recommendation, by leveraging both association matrix and similarity matrix within a regularized optimization process.

-   **Network-based proximity**: This approach measures relative proximity that quantifies the network-based relationship between drugs and disease proteins in the interactome. Given the set of disease proteins *S* and drug targets *T*, the proximity is the closest measure *d*(*s*, *t*), the shortest path length between nodes *s* and *t* in the network, which is defined $d(S,T) = \frac{1}{\left| \middle| T \middle| \right|}\sum\limits_{t \in T}\min_{s \in S}d(s,t)$. Proximity versus sensitivity and specificity curves is used to find the optimal proximity threshold.

-   **BiFusion-v2 (w/o PPI)**: To investigate the contribution of intradomain message passing operation in PPI network, we implemented a variant of our BiFusion model. We remove the second step of message passing to hide PPI information in each layer of encoder.

6 Results
=========

6.1 Performance comparison
--------------------------

In [Table 1](#btaa437-T1){ref-type="table"}, we found that BiFusion showed strong performance and outperformed other approaches by a large margin. Especially, BiFusion surpassed other methods without incorporating the graph structure information (cVAE and SSLM) by up to 22.3% (AUROC), highlighting the importance of graph-level information fusion for drug--disease findings. We also observed that our model achieved a gain of 8.2% (AUROC) over GCN operating on homogeneous graph, which indicated the effectiveness of bipartite graph convolution to model multirelational network. In addition, the protein feature smoothing operation allowed BiFusion a 2.4% gain (AUROC) over BiFusion-v2. Such finding supported that intradomain message passing operation can encourage information fusion in PPI network and thus enhanced the model performance on capturing complex interactions between drugs and diseases.

###### 

The summary of model performance on repoDB dataset under 10-fold cross validation

  Method                           AUROC               AUPRC         Overall accuracy    Drug-centric accuracy   Disease-centric accuracy
  ------------------------- ------------------- ------------------- ------------------- ----------------------- --------------------------
  BiFusion                   **0.857 ± 0.003**   **0.867 ± 0.003**   **0.738 ± 0.002**     **0.710 ± 0.003**        **0.705 ± 0.003**
  BiFusion-v2 (w/o PPI)        0.837 ± 0.003       0.810 ± 0.003       0.712 ± 0.003         0.687 ± 0.002            0.674 ± 0.003
  GCN                          0.792 ± 0.004       0.774 ± 0.005       0.700 ± 0.003         0.651 ± 0.004            0.659 ± 0.004
  DeepWalk                     0.769 ± 0.003       0.764 ± 0.003       0.672 ± 0.003         0.617 ± 0.003            0.637 ± 0.003
  cVAE                         0.743 ± 0.003       0.739 ± 0.003       0.665 ± 0.002         0.623 ± 0.003            0.616 ± 0.003
  SSLIM                        0.701 ± 0.002       0.703 ± 0.002       0.635 ± 0.002         0.590 ± 0.002            0.625 ± 0.002
  Network-based proximity      0.663 ± 0.004       0.678 ± 0.004       0.608 ± 0.004         0.568 ± 0.004            0.603 ± 0.005

The best results are highlighted in bold.

6.2 Investigation of novel predictions
--------------------------------------

To validate the ability of models for predicting truly novel drug-- disease associations (i.e. for new diseases without any treatment information), we further implemented a disjoint cross-validation fold-generation method (disease-centric cross validation) that ensures none of the diseases in onefold would appear in another fold. Specifically, all disease nodes were split into 10 equal-sized subsets during disease-centric cross validation. We clustered drug--disease pairs by disease nodes, then recombined pair clusters based on disease subsets resulting in 10 pair subsets. Each pair subset was used in turn as the testing set. We also performed 100 independent runs to report full distribution of average testing performance.

As shown in [Table 2](#btaa437-T2){ref-type="table"}, BiFusion achieved AUROC value of 0.775 and disease-centric accuracy value of 0.700, outperforming all baseline methods. We observe that BiFusion surpassed two other GCN-based methods by up to 6.7% (disease-centric accuracy), which showed the superior performance of our model on predicting novel drug--disease associations.

###### 

The results of novel predictions on repoDB dataset

  Method                           AUROC               AUPRC         Overall accuracy    Drug-centric accuracy   Disease-centric accuracy
  ------------------------- ------------------- ------------------- ------------------- ----------------------- --------------------------
  BiFusion                   **0.775 ± 0.003**   **0.794 ± 0.003**   **0.709 ± 0.002**       0.666 ± 0.003          **0.700 ± 0.003**
  BiFusion-v2 (w/o PPI)        0.749 ± 0.003       0.732 ± 0.003       0.674 ± 0.003         0.663 ± 0.003            0.668 ± 0.004
  GCN                          0.740 ± 0.004       0.726 ± 0.005       0.687 ± 0.004       **0.669 ± 0.004**          0.656 ± 0.005
  DeepWalk                     0.712 ± 0.004       0.700 ± 0.004       0.663 ± 0.003         0.647 ± 0.003            0.655 ± 0.004
  cVAE                         0.696 ± 0.003       0.698 ± 0.003       0.637 ± 0.002         0.631 ± 0.002            0.641 ± 0.003
  SSLIM                        0.671 ± 0.002       0.699 ± 0.003       0.616 ± 0.002         0.575 ± 0.003            0.591 ± 0.002
  Network-based proximity      0.661 ± 0.004       0.692 ± 0.004       0.622 ± 0.004         0.574 ± 0.004            0.594 ± 0.005

6.3 Experiments on the external dataset
---------------------------------------

To illustrate the potential generalization of our model, we performed evaluation on an external dataset ([@btaa437-B17]). Following the rule of collecting our primary dataset, we identified a total of 1234 associations containing 475 drugs and 141 diseases from the external dataset. We compared the performance of our method with baseline approaches under the same experiment settings as discussed. [Table 3](#btaa437-T3){ref-type="table"} showed the full distribution of average testing performance of 100 random runs. The results illustrated that BiFusion led best performance with AUROC value of 0.757, whereas GCN, DeepWalk, cVAE and SSLM have 0.717, 0.649, 0.676 and 0.652, respectively. BiFusion also achieved the best result in AUPRC with surpassing baseline methods by up to 24.5%.

###### 

The summary of model performance on external dataset

  Method                           AUROC               AUPRC         Overall accuracy    Drug-centric accuracy   Disease-centric accuracy
  ------------------------- ------------------- ------------------- ------------------- ----------------------- --------------------------
  BiFusion                   **0.757 ± 0.005**   **0.721 ± 0.004**     0.671 ± 0.004       **0.675 ± 0.004**        **0.653 ± 0.004**
  BiFusion-v2 (w/o PPI)        0.722 ± 0.005       0.677 ± 0.005     **0.675 ± 0.005**       0.670 ± 0.004            0.636 ± 0.005
  GCN                          0.717 ± 0.004       0.676 ± 0.004       0.664 ± 0.003         0.667 ± 0.003            0.624 ± 0.004
  DeepWalk                     0.649 ± 0.003       0.628 ± 0.003       0.611 ± 0.003         0.604 ± 0.003            0.572 ± 0.003
  cVAE                         0.676 ± 0.006       0.653 ± 0.005       0.637 ± 0.005         0.629 ± 0.006            0.639 ± 0.006
  SSLIM                        0.652 ± 0.003       0.607 ± 0.003       0.602 ± 0.002         0.614 ± 0.003            0.625 ± 0.003
  Network-based proximity      0.610 ± 0.003       0.579 ± 0.002       0.573 ± 0.003         0.566 ± 0.002            0.563 ± 0.003

6.4 Case study
--------------

We conducted a case study to further assess the quality of our model's novel predictions by performing a literature-based evaluation of new hits. Specifically, we applied BiFusion to predict candidate drugs for two diseases including breast carcinoma and Parkinson's disease (PD). After the prediction scores of all candidate pairs are computed, we generate a ranked list of drug--disease associations by the predicted scores. We then identified novel associations by excluding all the known drug--disease associations from the primary dataset. [Table 4](#btaa437-T4){ref-type="table"} shows candidate drugs with evidences.

###### 

New candidate drugs ranked by prediction scores by BiFusion for breast carcinoma and Parkinson's disease

  Diseases            Rank   Candidate drugs    Evidences
  ------------------- ------ ------------------ ---------------------------------------------------
  Breast carcinoma    1      Clofarabine        [@btaa437-B34] and [@btaa437-B33]
                      3      Cimetidine         [@btaa437-B2]
                      4      Thiamine           [@btaa437-B32]
                      5      Arsenic trioxide   [@btaa437-B65] and [@btaa437-B49]
  Parkinson disease   1      Dextromethorphan   [@btaa437-B13] and [@btaa437-B14]
                      2      Solifenacin        [@btaa437-B63]
                      4      Atomoxetine        [@btaa437-B56], [@btaa437-B45] and [@btaa437-B59]
                      7      Venlafaxine        [@btaa437-B3]
                      8      Tapentadol         [@btaa437-B53]

-   **Breast carcinoma:** Among the top five predicted drugs in the rank list, four drugs (80% success rate) were validated by various literature evidences. Arsenic trioxide was predicted by BiFusion to be associated with breast carcinoma, which is supported by recent reports. For example [@btaa437-B65] showed arsenic trioxide suppresses cell growth and migration via inhibition of miR-27a in breast cancer cells. [@btaa437-B49] found that arsenic trioxide suppressed cell growth, stimulated apoptosis and retarded cell invasion partly via upregulation of let-7a in breast cancer cells. Clofarabine (CIF) is also one of the top predicted candidates for treating breast carcinoma. [@btaa437-B34] provided the first evidence of CIF implications in epigenetic regulation of transcriptional activity of selected tumor suppressor genes in breast cancer. [@btaa437-B33] demonstrated the ability of ClF-based combinations with polyphenols to promote cancer cell death and reactivate DNA methylation-silenced tumor suppressor genes in breast cancer cells. In addition, BiFusion found that Cimetidine and Thiamine were associated with breast cancer, which was supported by several evidences ([@btaa437-B2]; [@btaa437-B32]).

-   **Parkinson's disease**: PD is a neurodegenerative disease currently without efficacious treatments available yet. Among top 10 predicted candidates, we found 5 drugs were validated by literature. For example dextromethorphan is the top predicted candidate. Despite approval by the FDA for pseudobulbar affect based on studies of patients with amyotrophic lateral sclerosis or multiple sclerosis, [@btaa437-B13] and [@btaa437-B14] provided evidence of clinical benefit with dextromethorphan--quinidine for treating PD. Atomoxetine was also predicted by our model to be associated with PD. Such prediction can be supported by a previous study ([@btaa437-B59]), indicating that atomoxetine can enhanced prefrontal cortical activation and frontostriatal connectivity and may improve response inhibition in PD. The results of [@btaa437-B45] also suggested that atomoxetine restores the response inhibition network in PD.

6.5 The effect of layer numbers on model performance
----------------------------------------------------

To investigate the effect of layer numbers on model performance, we compared results with different number of layers in BiFusion on the repoDB dataset. We performed 100 independent cross-validation runs and reported the mean value of AUROC and AUPRC. [Figure 3](#btaa437-F3){ref-type="fig"} showed the model performance along with the increase of layer numbers. We observed that one layer has the lowest performance, suggesting that a shallow bipartite GCN cannot sufficiently propagate the node feature to fuse heterogeneous information, especially for the complex drug--protein--disease network. Meanwhile, we found that BiFusion achieved significant improvement with two layers' structure. But with more than two layers, the model performance tends to decrease. This finding may be explained that GCN model is viewed as a special form of Laplacian smoothing that over-smoothing occurs with too many convolutional layers ([@btaa437-B30]). Thus, if BiFusion's layers are going too deep, the output embedding features can be over-smoothed and less differentiated from different classes.

![Effect of the number of layers on model performance. The *x* axis denotes the number of BiFusion layers and the *y* axis is the model performance on testing set](btaa437f3){#btaa437-F3}

7 Conclusion
============

In this study, we presented a novel bipartite GCNs toward heterogeneous information fusion for computational DR. Our BiFusion model achieved information fusion via an important interdomain message passing across drug-, disease- and protein-level information. Extensive experiments have demonstrated that our model achieves strong performance on the task of DR. In addition, we externally validated results that have confirmed the potential generalization of our approach for DR. Case study offers concrete examples that reaffirmed medical usefulness of our approach. In the future work, we plan to assess model performance by exploring scalable cohorts with clinically validated associations between drugs and diseases. As our approach supports multilevel biological information fusion, additional pharmaceutical information such as drug side effects information can be also considered to improve our network analysis.
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